US Patent 7652070 Treatment method for MMP-implicated pathologies

A treatment method for pathologies in which increased levels of MMP production are implicated in pathogenesis. Examples of such pathologies include pterygium, kerataconus, and macular degeneration. Treatment is based on administration of cysteamine in therapeutically effective amounts. Treatment may be in one of several alternative forms, including eye drops and oral applications. Administration in the form of eye drops may be preferred for pathologies affecting the eyes.